Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session A: Prostate Cancer
Link to Abstracts
Link to Posters: Sie müssen bei ASCO-GU eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Die Abstracts sind frei zugänglich. Hier können Sie die Registrierung erwerben.
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
Presenter: Guillaume Grisay, MD. Centre Hospitalier Jolimont
Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer.
Presenter: Shaogang Wang, MD. Huazhong University of Science and Technology
Measuring oncological value of exercise and statin: Can we improve the prognosis of patients with cancer and change the microenvironment in different tumor types with exercise and statins (MOVES study)?
Presenter: Jorma T.J Sormunen, MD, PhD, MBA. University of Tampere
Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).
Presenter: Giulio Francolini, MD. Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence
Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.
Presenter: Arun Azad, PhD, MBBS, FRACP. Peter MacCallum Cancer Centre
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.
Presenter: Susanna Varkey Ulahannan, MD. University of Okahoma Health Sciences Center
Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.
Presenter: Jorge Esteban Villarrubia, MD. Medical Oncology Department, 12 de Octubre University Hospital
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
Presenter: Yu-Wei Chen, MD, MS. Moores Cancer Center at UC San Diego Health
A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).
Presenter: Kristine Peregrino Lacuna, MD, CCRP. Columbia University Irving Medical Center
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
Presenter: Evan Y. Yu, MD. Fred Hutchinson Cancer Research Center
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Sumit Kumar Subudhi, MD, PhD. The University of Texas MD Anderson Cancer Center
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
Presenter: Andrew Leonard Laccetti, MD, MS. Memorial Sloan Kettering Cancer Center
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
Presenter: Xiao X. Wei, MD. Dana-Farber Cancer Institute
A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer.
Presenter: Jingsong Zhang, MD, PhD. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
Presenter: Geoffrey Johnson, MD, PhD. Mayo Clinic Rochester
COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.
Presenter: Luke T. Nordquist, MD. Urology Cancer Center, PC
A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Pier VItale Nuzzo, MD, PhD. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
Presenter: Evan Y. Yu, MD. University of Washington
Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
Presenter: Evan Y. Yu, MD. University of Washington
CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Gliceida Galarza Fortuna, MD. Huntsman Cancer Institute at the University of Utah
A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).
Presenter: Arya Mariam Roy, MD. Roswell Park Comprehensive Cancer Center
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).
Presenter: Nat Lenzo, MD. Genesiscare
Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Presenter: Alex Chehrazi-Raffle, MD. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
Presenter: Erin Catherine Welch, BS. University of Pennsylvania-Abramson Cancer Center, Perelman Center for Advanced Medicine
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
Presenter: Neel Patel. Telix Pharmaceuticals
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
Presenter: Jonathan Alexander Chatzkel, MD. University of Florida/UF Health Cancer Center
Borxpten: A phase II study of bortezomib (B) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion.
Presenter: Vinay Mathew Thomas, MBBS. Huntsman Cancer Institute at the University of Utah
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
Presenter: Luke T. Nordquist, MD. Urology Cancer Center, PC
Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.
Presenter: Zachariah Taylor, DO. Main Line Health
Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.
Presenter: Jose Mauricio Mota, MD, PhD. Instituto D'Or de Pesquisa e Ensino
A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).
Presenter: Guilhem Roubaud, MD. Department of Medical Oncology, Institut Bergonié
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
Presenter: Zin Myint, MD. University of Kentucky
Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.
Presenter: Zin Myint, MD. University of Kentucky
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
Presenter: Ulrich Krafft, MD. University Hospital Essen, Universtity Duisburg-Essen, Germany
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).
Presenter: Rana R. McKay, MD. University of California, San Diego
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.
Presenter: Heather H. Cheng, MD, PhD. Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center
Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.
Presenter: Shun Zhang, MS. Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.
Presenter: Simon Pacey, PhD, FRCP. Cambridge University Hospitals NHS Foundation Trust & University of Cambridge
Prostate screening for men with inherited risk of developing aggressive prostate cancer: The PATROL study.
Presenter: Heather H. Cheng, MD, PhD. Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center